180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders”
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report”
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award”
Related Editorial In a natural response to injury or infection, the body produces chemicals that trigger the immune system to release antibodies and proteins plus increase blood flow to the afflicted area, which aids healing and produces inflammation. However, the immune system and the inflammatory processes have pernicious aspects far removed from beneficial healing. In … Continue reading “NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) Developing Groundbreaking Anti-Inflammatory Therapeutics”
180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in November 2020. The letter noted the company’s achievement in both legacy-related issues and strengthening its … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Stockholder Letter”
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The conference is slated to take place … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Inaugural Emerging Growth Virtual Conference”
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced the closing of its previously announced private placement. The private placement included 2,564,000 shares of common stock and accompanying warrants, each share sold for a combined … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Private Placement with Gross Proceeds of $11.7M”
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into securities purchase agreements with certain institutional investors to raise approximately $11.7 million through the private placement of 2,564,000 shares of its common stock and … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $11.7M Private Placement”
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Biotech Showcase(TM) Digital 2021 Conference. According to the update, the conference is taking place … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at the Biotech Showcase(TM) Digital 2021 Conference”
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Tuesday announced that it will present at the H.C. Wainwright Bioconnect 2021 Conference. According to the update, the presentation will be … Continue reading “NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Upcoming H.C. Wainwright Bioconnect Conference”
